Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C MutationAdrian G. Sacher, Jayesh Desai, Alejandro Falcón et al.|New England Journal of Medicine|2023Cited by 307
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trialJayesh Desai, Guzmán Alonso, Se Hyun Kim et al.|Nature Medicine|2023Cited by 128
Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with <i>KRAS G12C</i> mutationJayesh Desai, Manish Patel, Sae‐Won Han et al.|Cancer Research|2023Cited by 10
Abstract P2-01-16: Pharmacogenomic variants and risk of adverse events in breast cancer patients treated with Trastuzumab-deruxtecan: results from the PROCURE projectRodrigo Sánchez-Bayona, Cristina Rodríguez‐Antona, Javier de Nicolás‐Hernández et al.|Clinical Cancer Research|2025Cited by 3